Sterling Capital Management’s Oric Pharmaceuticals ORIC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$21.6K Sell
1,701
-1,137
-40% -$12.9K ﹤0.01% 1997
2025
Q4
$23.2K Sell
2,838
-71
-2% -$817 ﹤0.01% 2145
2025
Q3
$34.9K Buy
2,909
+2,008
+223% +$21.1K ﹤0.01% 1898
2025
Q2
$9.14K Buy
901
+67
+8% +$450 ﹤0.01% 2183
2025
Q1
$4.65K Sell
834
-702
-46% -$6.14K ﹤0.01% 2198
2024
Q4
$12.4K Buy
1,536
+1,354
+744% +$12.4K ﹤0.01% 2066
2024
Q3
$1.87K Buy
+182
New +$1.8K ﹤0.01% 2217

Other funds holding ORIC

Sterling Capital Management's ORIC Position: Q1 2026 in Review

Sterling Capital Management reduced its Oric Pharmaceuticals (ORIC) stake by 40% in Q1 2026, selling an estimated $12.9K and leaving 1,701 shares worth $21.6K. The position accounts for ﹤0.01% of the portfolio, ranked #1997.

Sterling Capital Management first reported a position in ORIC in Q3 2024 and has held it in 7 quarters since. The position peaked at $34.9K in Q3 2025. 182 funds tracked by Wall St. Rank hold ORIC as of Q1 2026.

  • Sterling Capital Management held 1,701 shares of Oric Pharmaceuticals worth $21.6K as of Q1 2026.
  • Sterling Capital Management sold 1,137 Oric Pharmaceuticals shares in Q1 2026, an estimated $12.9K.
  • Oric Pharmaceuticals made up ﹤0.01% of Sterling Capital Management's portfolio in Q1 2026, its #1997 holding.
  • Sterling Capital Management first reported a position in Oric Pharmaceuticals in Q3 2024 and has held it in 7 quarters since.
  • Sterling Capital Management's Oric Pharmaceuticals position peaked at $34.9K in Q3 2025.
  • 182 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q1 2026.

Based on Sterling Capital Management's 13F filing for Q1 2026, filed 22 Apr 2026.